

Global Market Study on Sickle Cell Disease Treatment: Sickle Cell Anaemia Anticipated to be the Most Lucrative Disease Type Segment Through 2025

<https://marketpublishers.com/r/G36086A9180EN.html>

Date: September 2017

Pages: 224

Price: US\$ 4,900.00 (Single User License)

ID: G36086A9180EN

Abstracts

Persistence Market Research has come up with a new report titled “Sickle Cell Disease Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025),” for the projected period of 8-years. According to this report, weighted average selling price has been considered to estimate the market size of various drugs mentioned in the scope of the study. We have not only captured the country price with the local currency but also the local currency figures is converted to USD to offer forecasts in a consistent currency standard. Furthermore, we have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions of country. Prices considered in the models are standardized based on the average dosage used per Sickle cell disease treatment per dosage in a year. Availability of branded off-patent equivalents have been taken into consideration while calculating prices.

We have used following parameters to estimate the global market size

Market sizing is done using our in-house epidemiology data based model to estimate sickle cell disease treatment market. We adopt bottom-up approach to forecast sickle cell disease treatment market globally. The following parameters are used to estimate the market size for the base year 2016:

Country level data for prevalence and incidence rate for calculating base population

Diagnosis rate

Treatment rate and percentage adoption of currently available treatment options

in various stages of the disease for calculating target population

Average cost of drug treatment cycle associated with the each treatment option

Average cost of each cycle is then multiplied by average number of cycles taken by patients for all drug type (differs from drug to drug) in an year

We have used a number of sources to present a detailed analysis of the global sickle cell disease treatment market

Our research methodology uses both primary and secondary research to collect the relevant data. We have analyzed the market by considering the revenue through extensive primary research to understand the usage pattern, historic trends, and problems faced by the physicians, the required treatment developments, and most preferred drugs. Key opinion leaders were considered for the primary research that included experienced healthcare professionals in various healthcare facilities at country level. These estimates were further validated with drug manufacturers, distributors, and suppliers.

Extensive secondary research has been carried out to understand the epidemiology of sickle cell disease, treatment rate, adoption rate, regulatory scenarios, average selling price, reimbursement scenario, by referring published scientific literature from various databases such as the WHO, National Heart, Lung, and Blood Institute (NHLBI), PubMed, Springer, and Wiley among many others. We have also analyzed various companies' annual report, investor presentation, SEC filings, 10k reports and press release operating in sickle cell disease treatment market to fetch substantial information about the market size, trends, opportunity, drivers, and restraints to analyze key players.

Report Inclusions and Exclusions

In this report, we have considered only those drugs that are administered for sickle cell disease treatment. The study includes drugs such as hydroxyurea, antibiotics, pain-relieving medications and others. The drugs considered in others segments are drugs that are administered based on patients conditions and also includes the newly FDA approved drug L-Glutamine for sickle cell disease treatment.

We have not included other therapies such as surgeries, blood transfusions, gene

therapies and bone marrow transplantation etc. to calculate market value in this study. The market also do not includes any products from the drug type segment administered to patients of any other indications. The market value is calculated based on only the drug type (Hydroxyurea, Antibiotics, Pain-relieving medications, and other drugs) administered for sickle cell disease treatment.

Forecast Assumptions and Limitations

To forecast the market we have considered the following assumptions:

- Growth in diagnosis and treatment rate

- Change in price of drugs

- Adoption curve for available treatment

- Impact of launch of new combination regimen which are in late stage of development

Forecasting has been done on a static base and only currently approved products have been taken into consideration for calculating the actual size of the treatment market

Our clients should note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting is done on our internal proprietary model which also uses different macro-economic factors and industry based demand driving factors that are impacting the market and its forecast trends apart from disease related factors.

Contents

1. EXECUTIVE SUMMARY

- 1.1. Market Overview
- 1.2. Market Analysis
- 1.3. PMR Analysis and Recommendations
- 1.4. Wheel of Fortune

2. MARKET INTRODUCTION

- 2.1. Market Definition
- 2.2. Market Taxonomy

3. MARKET VIEW POINT

- 3.1. Opportunity Analysis
- 3.2. Global Market Drivers
 - 3.2.1. Macroeconomic Drivers
 - 3.2.2. Demand-side Drivers
 - 3.2.3. Supply-side Drivers
- 3.3. Global Market Restraints
- 3.4. Global Market Trends
- 3.5. Epidemiology data of Sickle cell Disease, 2015
- 3.6. Epidemiology data of Sickle cell Disease 3.7. Product Pipeline Analysis

4. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025

- 4.1. Introduction
- 4.2. Regional Market Dynamics
 - 4.2.1. Drivers
 - 4.2.2. Restraints
- 4.3. Historical Market Size (US\$ Mn) Analysis By Country, 2012–2016
 - 4.3.1. U.S.
 - 4.3.2. Canada
- 4.4. Market Size (US\$ Mn) and Forecast By Country, 2017–2025
 - 4.4.1. U.S.
 - 4.4.2. Canada

- 4.5. Historical Market Size (US\$ Mn) Analysis By Drug Type, 2012–2016
 - 4.5.1. Hydroxyurea
 - 4.5.2. Antibiotics
 - 4.5.3. Pain-relieving Medications
 - 4.5.4. Others
- 4.6. Market Size (US\$ Mn) Forecast By Drug Type, 2017–2025
 - 4.6.1. Hydroxyurea
 - 4.6.2. Antibiotics
 - 4.6.3. Pain-relieving Medications
 - 4.6.4. Others
- 4.7. Historical Market Size (US\$ Mn) Analysis By Disease Type, 2012–2016
 - 4.7.1. Sickle cell anemia
 - 4.7.2. Sickle hemoglobin C disease
 - 4.7.3. Sickle beta thalassemia
 - 4.7.4. Others
- 4.8. Market Size (US\$ Mn) and Forecast, By Disease Type, 2017–2025
 - 4.8.1. Sickle cell anemia
 - 4.8.2. Sickle hemoglobin C disease
 - 4.8.3. Sickle beta thalassemia
 - 4.8.4. Others
- 4.9. Historical Market Size (US\$ Mn) Analysis By Distribution Channel, 2012–2016
 - 4.9.1. Hospital Pharmacies
 - 4.9.2. Retail Pharmacies
 - 4.9.3. Online Pharmacies
- 4.10. Market Size (US\$ Mn) and Forecast, By Distribution Channel, 2017–2025
 - 4.10.1. Hospital Pharmacies
 - 4.10.2. Retail Pharmacies
 - 4.10.3. Online Pharmacies
- 4.11. Drivers and Restraints: Impact Analysis
- 4.12. Market Attractiveness Analysis
 - 4.12.1. By Country
 - 4.12.2. By Drug Type
 - 4.12.3. By Disease Type
 - 4.12.4. By Distribution Channel

5. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025

5.1. Introduction

- 5.2. Regional Market Dynamics
 - 5.2.1. Drivers
 - 5.2.2. Restraints
 - 5.2.3. Trends
- 5.3. Historical Market Size (US\$ Mn) Analysis By Country, 2012–2016
 - 5.3.1. Brazil
 - 5.3.2. Mexico
 - 5.3.3. Rest of Latin America
- 5.4. Market Size (US\$ Mn) and Forecast By Country, 2017–2025
 - 5.4.1. Brazil
 - 5.4.2. Mexico
 - 5.4.3. Rest of Latin America
- 5.5. Historical Market Size (US\$ Mn) Analysis By Drug Type, 2012–2016
 - 5.5.1. Hydroxyurea
 - 5.5.2. Antibiotics
 - 5.5.3. Pain-relieving Medications
 - 5.5.4. Others
- 5.6. Market Size (US\$ Mn) Forecast By Drug Type, 2017–2025
 - 5.6.1. Hydroxyurea
 - 5.6.2. Antibiotics
 - 5.6.3. Pain-relieving Medications
 - 5.6.4. Others
- 5.7. Historical Market Size (US\$ Mn) Analysis By Disease Type, 2012–2016
 - 5.7.1. Sickle cell anemia
 - 5.7.2. Sickle hemoglobin C disease
 - 5.7.3. Sickle beta thalassemia
 - 5.7.4. Others
- 5.8. Market Size (US\$ Mn) and Forecast, By Disease Type, 2017–2025
 - 5.8.1. Sickle cell anemia
 - 5.8.2. Sickle hemoglobin C disease
 - 5.8.3. Sickle beta thalassemia
 - 5.8.4. Others
- 5.9. Historical Market Size (US\$ Mn) Analysis By Distribution Channel, 2012–2016
 - 5.9.1. Hospital Pharmacies
 - 5.9.2. Retail Pharmacies
 - 5.9.3. Online Pharmacies
- 5.10. Market Size (US\$ Mn) and Forecast, By Distribution Channel, 2017–2025
 - 5.10.1. Hospital Pharmacies
 - 5.10.2. Retail Pharmacies

- 5.10.3. Online Pharmacies
- 5.11. Drivers and Restraints: Impact Analysis
- 5.12. Market Attractiveness Analysis
 - 5.12.1. By Country
 - 5.12.2. By Drug Type
 - 5.12.3. By Disease Type
 - 5.12.4. By Distribution Channel

6. EUROPE SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025

- 6.1. Introduction
- 6.2. Regional Market Dynamics
 - 6.2.1. Drivers
 - 6.2.2. Restraints
- 6.3. Historical Market Size (US\$ Mn) Analysis By Country, 2012–2016
 - 6.3.1. Germany
 - 6.3.2. France
 - 6.3.3. U.K.
 - 6.3.4. Spain
 - 6.3.5. Italy
 - 6.3.6. Russia
 - 6.3.7. Rest of Europe
- 6.4. Market Size (US\$ Mn) and Forecast By Country, 2017–2025
 - 6.4.1. Germany
 - 6.4.2. France
 - 6.4.3. U.K.
 - 6.4.4. Spain
 - 6.4.5. Italy
 - 6.4.6. Russia
 - 6.4.7. Rest of Europe
- 6.5. Historical Market Size (US\$ Mn) Analysis By Drug Type, 2012–2016
 - 6.5.1. Hydroxyurea
 - 6.5.2. Antibiotics
 - 6.5.3. Pain-relieving Medications
 - 6.5.4. Others
- 6.6. Market Size (US\$ Mn) Forecast By Drug Type, 2017–2025
 - 6.6.1. Hydroxyurea
 - 6.6.2. Antibiotics

- 6.6.3. Pain-relieving Medications
- 6.6.4. Others
- 6.7. Historical Market Size (US\$ Mn) Analysis By Disease Type, 2012–2016
 - 6.7.1. Sickle cell anemia
 - 6.7.2. Sickle hemoglobin C disease
 - 6.7.3. Sickle beta thalassemia
 - 6.7.4. Others
- 6.8. Market Size (US\$ Mn) and Forecast, By Disease Type, 2017–2025
 - 6.8.1. Sickle cell anemia
 - 6.8.2. Sickle hemoglobin C disease
 - 6.8.3. Sickle beta thalassemia
 - 6.8.4. Others
- 6.9. Historical Market Size (US\$ Mn) Analysis By Distribution Channel, 2012–2016
 - 6.9.1. Hospital Pharmacies
 - 6.9.2. Retail Pharmacies
 - 6.9.3. Online Pharmacies
- 6.10. Market Size (US\$ Mn) and Forecast, By Distribution Channel, 2017–2025
 - 6.10.1. Hospital Pharmacies
 - 6.10.2. Retail Pharmacies
 - 6.10.3. Online Pharmacies
- 6.11. Drivers and Restraints: Impact Analysis
- 6.12. Market Attractiveness Analysis
 - 6.12.1. By Country
 - 6.12.2. By Drug Type
 - 6.12.3. By Disease Type
 - 6.12.4. By Distribution Channel

7. ASIA PACIFIC SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025

- 7.1. Introduction
- 7.2. Regional Market Dynamics
 - 7.2.1. Drivers
 - 7.2.2. Restraints
- 7.3. Historical Market Size (US\$ Mn) Analysis By Country, 2012–2016
 - 7.3.1. China
 - 7.3.2. India
 - 7.3.3. Japan
 - 7.3.4. Australia and New Zealand

- 7.3.5. ASEAN
- 7.3.6. Rest of ASIA PACIFIC
- 7.4. Market Size (US\$ Mn) and Forecast By Country, 2017–2025
 - 7.4.1. China
 - 7.4.2. India
 - 7.4.3. Japan
 - 7.4.4. Australia and New Zealand
 - 7.4.5. ASEAN
 - 7.4.6. Rest of Asia Pacific
- 7.5. Historical Market Size (US\$ Mn) Analysis By Drug Type, 2012–2016
 - 7.5.1. Hydroxyurea
 - 7.5.2. Antibiotics
 - 7.5.3. Pain-relieving Medications
 - 7.5.4. Others
- 7.6. Market Size (US\$ Mn) Forecast By Drug Type, 2017–2025
 - 7.6.1. Hydroxyurea
 - 7.6.2. Antibiotics
 - 7.6.3. Pain-relieving Medications
 - 7.6.4. Others
- 7.7. Historical Market Size (US\$ Mn) Analysis By Disease Type, 2012–2016
 - 7.7.1. Sickle cell anemia
 - 7.7.2. Sickle hemoglobin C disease
 - 7.7.3. Sickle beta thalassemia
 - 7.7.4. Others
- 7.8. Market Size (US\$ Mn) and Forecast, By Disease Type, 2017–2025
 - 7.8.1. Sickle cell anemia
 - 7.8.2. Sickle hemoglobin C disease
 - 7.8.3. Sickle beta thalassemia
 - 7.8.4. Others
- 7.9. Historical Market Size (US\$ Mn) Analysis By Distribution Channel, 2012–2016
 - 7.9.1. Hospital Pharmacies
 - 7.9.2. Retail Pharmacies
 - 7.9.3. Online Pharmacies
- 7.10. Market Size (US\$ Mn) and Forecast, By Distribution Channel, 2017–2025
 - 7.10.1. Hospital Pharmacies
 - 7.10.2. Retail Pharmacies
 - 7.10.3. Online Pharmacies
- 7.11. Drivers and Restraints: Impact Analysis
- 7.12. Market Attractiveness Analysis

- 7.12.1. By Country
- 7.12.2. By Drug Type
- 7.12.3. By Disease Type
- 7.12.4. By Distribution Channel

8. MEA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025

- 8.1. Introduction
- 8.2. Regional Market Dynamics
 - 8.2.1. Drivers
 - 8.2.2. Restraints
- 8.3. Historical Market Size (US\$ Mn) Analysis By Country, 2012–2016
 - 8.3.1. GCC Countries
 - 8.3.2. South Africa
 - 8.3.3. Rest of MEA
- 8.4. Market Size (US\$ Mn) and Forecast By Country, 2017–2025
 - 8.4.1. GCC Countries
 - 8.4.2. South Africa
 - 8.4.3. Rest of MEA
- 8.5. Historical Market Size (US\$ Mn) Analysis By Drug Type, 2012–2016
 - 8.5.1. Hydroxyurea
 - 8.5.2. Antibiotics
 - 8.5.3. Pain-relieving Medications
 - 8.5.4. Others
- 8.6. Market Size (US\$ Mn) Forecast By Drug Type, 2017–2025
 - 8.6.1. Hydroxyurea
 - 8.6.2. Antibiotics
 - 8.6.3. Pain-relieving Medications
 - 8.6.4. Others
- 8.7. Historical Market Size (US\$ Mn) Analysis By Disease Type, 2012–2016
 - 8.7.1. Sickle cell anemia
 - 8.7.2. Sickle hemoglobin C disease
 - 8.7.3. Sickle beta thalassemia
 - 8.7.4. Others
- 8.8. Market Size (US\$ Mn) and Forecast, By Disease Type, 2017–2025
 - 8.8.1. Sickle cell anemia
 - 8.8.2. Sickle hemoglobin C disease
 - 8.8.3. Sickle beta thalassemia

8.8.4. Others

8.9. Historical Market Size (US\$ Mn) Analysis By Distribution Channel, 2012–2016

8.9.1. Hospital Pharmacies

8.9.2. Retail Pharmacies

8.9.3. Online Pharmacies

8.10. Market Size (US\$ Mn) and Forecast, By Distribution Channel, 2017–2025

8.10.1. Hospital Pharmacies

8.10.2. Retail Pharmacies

8.10.3. Online Pharmacies

8.11. Drivers and Restraints: Impact Analysis

8.12. Market Attractiveness Analysis

8.12.1. By Country

8.12.2. By Drug Type

8.12.3. By Disease Type

8.12.4. By Distribution Channel

9. FORECAST ASSUMPTIONS

10. COMPETITION LANDSCAPE

10.1. Competition Dashboard

10.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

10.2.1. AstraZeneca Plc.

10.2.2. Eli Lilly and Company

10.2.3. Bristol-Myers Squibb Company

10.2.4. Novartis AG

10.2.5. Pfizer Inc.

10.2.6. Baxter International Inc.

10.2.7. Emmaus Life Sciences, Inc.

10.2.8. Bluebird bio, Inc.

10.2.9. Global Blood Therapeutics Inc.

10.2.10. Sangamo Therapeutics, Inc.

10.2.11. Acceleron Pharma, Inc.

10.2.12. Arena Pharmaceuticals, Inc.

10.2.13. Alnylam Pharmaceuticals, Inc.

11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY REGION

- 11.1.Introduction / Key Findings
- 11.2.Historical Market Size (US\$ Mn) Analysis By Region, 2012-2016
 - 11.2.1. North America
 - 11.2.2. Latin America
 - 11.2.3. Europe
 - 11.2.4. Asia Pacific
 - 11.2.5. MEA
- 11.3.Market Size (US\$ Mn) Forecast By Region, 2017-2025
 - 11.3.1. North America
 - 11.3.2. Latin America
 - 11.3.3. Europe
 - 11.3.4. Asia Pacific
 - 11.3.5. MEA
- 11.4.Market Attractiveness Analysis By Region

12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY DRUG TYPE

- 12.1.Introduction
- 12.2.Historical Market Size (US\$ Mn) Analysis By Drug Type, 2012–2016
 - 12.2.1. Hydroxyurea
 - 12.2.2. Antibiotics
 - 12.2.3. Pain-relieving Medications
 - 12.2.4. Others
- 12.3.Market Size (US\$ Mn) Forecast By Drug Type, 2017–2025
 - 12.3.1. Hydroxyurea
 - 12.3.2. Antibiotics
 - 12.3.3. Pain-relieving Medications
 - 12.3.4. Others
- 12.4.Market Attractiveness Analysis By Drug Type

13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY DISEASE TYPE

- 13.1.Introduction
- 13.2.Historical Market Size (US\$ Mn) Analysis By Disease Type, 2012–2016
 - 13.2.1. Sickle cell anemia
 - 13.2.2. Sickle hemoglobin C disease

13.2.3. Sickle beta thalassemia

13.2.4. Others

13.3. Market Size (US\$ Mn) and Forecast, By Disease Type, 2017–2025

13.3.1. Sickle cell anemia

13.3.2. Sickle hemoglobin C disease

13.3.3. Sickle beta thalassemia

13.3.4. Others

13.4. Market Attractiveness Analysis By Disease Type

14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY DISTRIBUTION CHANNEL

14.1. Introduction

14.2. Historical Market Size (US\$ Mn) Analysis By Distribution Channel, 2012-2016

14.2.1. Hospital Pharmacies

14.2.2. Retail Pharmacies

14.2.3. Online pharmacies

14.3. Market Size (US\$ Mn) and Forecast By Distribution Channel, 2017-2025

14.3.1. Hospital Pharmacies

14.3.2. Retail Pharmacies

14.3.3. Online pharmacies

14.4. Market Attractive Analysis By Distribution Channel

15. GLOBAL MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025

15.1. Market Size and Y-o-Y Growth

15.2. Absolute \$ Opportunity

16. RESEARCH METHODOLOG

List Of Tables

LIST OF TABLES

Table 1: Epidemiology data of Sickle cell Disease 2015

Table 2: Epidemiology data of Sickle cell Disease Table 3: Pipeline Products

Table 4: North America Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country

Table 5: North America Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type

Table 6: North America Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type

Table 7: Latin America Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country

Table 8: Latin America Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type

Table 9: Latin America Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type

Table 10: Europe Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country

Table 11: Europe Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type

Table 12: Europe Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type

Table 13: APAC Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country

Table 14: APAC Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type

Table 15: APAC Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type

Table 16: MEA Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country

Table 17: MEA Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type

Table 18: MEA Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type

Table 19: Global Sickle Cell Disease Treatment Market Size (US\$ Mn) 2012–2016 and Forecast 2017-2025 By Region

Table 20: Global Sickle Cell Disease Treatment Market Size (US\$ Mn) 2012–2016 and

Forecast, 2017-2025, By Drug Type

Table 21: Global Sickle Cell Disease Treatment Market Size (US\$ Mn) 2012–2016 and Forecast, 2017-2025, By Disease Type

Table 22: Global Sickle Cell Disease Treatment Market Size (US\$ Mn) 2012–2016 and Forecast 2017-2025, By Distribution Channel

List Of Figures

LIST OF FIGURES

Figure 1: Global Sickle Cell Disease Treatment Market Revenue Share, By Drug Type (2017)

Figure 2: Global Sickle Cell Disease Treatment Market Revenue Share, By Indication (2017)

Figure 3: Global Sickle Cell Disease Treatment Market Revenue Share, By Distribution Channel (2017)

Figure 4: North America Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)

Figure 5: North America Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)

Figure 6: North America Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)

Figure 7: North America Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)

Figure 8: North America Sickle Cell Disease Treatment Market Value (US\$ Mn) & Forecast 2017 & 2025

Figure 9: North America Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis, 2012–2016

Figure 10: North America Sickle Cell Disease Treatment Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 11: North America Hydroxyurea Market Size (US\$ Mn) Analysis, 2012–2016

Figure 12: North America Hydroxyurea Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 13: North America Antibiotics Market Size (US\$ Mn) Analysis, 2012–2016

Figure 14: North America Antibiotics Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 15: North America Pain-relieving Medications Market Size (US\$ Mn) Analysis, 2012–2016

Figure 16: North America Pain-relieving Medications Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 17: North America Others Market Size (US\$ Mn) Analysis, 2012–2016

Figure 18: North America Others Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 19: North America Sickle cell anemia Market Size (US\$ Mn) Analysis, 2012–2016

Figure 20: North America Sickle cell anemia Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 21: North America Sickle Hemoglobin C Disease Market Size (US\$ Mn) Analysis, 2012–2016

Figure 22: North America Sickle Hemoglobin C Disease Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 23: North America Sickle Beta Thalassemia Market Size (US\$ Mn) Analysis, 2012–2016

Figure 24: North America Sickle Beta Thalassemia Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 25: North America Hospital Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 26: North America Hospital Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 27: North America Retail Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 28: North America Retail Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 29: North America Online Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 30: North America Online Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 31: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type

Figure 32: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type

Figure 33: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel

Figure 34: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country

Figure 35: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)

Figure 36: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)

Figure 37: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)

Figure 38: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)

Figure 40: Latin America Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis,

2012–2016

Figure 41: Latin America Sickle Cell Disease Treatment Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 42: Latin America Hydroxyurea Market Size (US\$ Mn) Analysis, 2012–2016

Figure 43: Latin America Hydroxyurea Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 44: Latin America Antibiotics Market Size (US\$ Mn) Analysis, 2012–2016

Figure 45: Latin America Antibiotics Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 46: Latin America Pain-relieving Medications Market Size (US\$ Mn) Analysis, 2012–2016

Figure 47: Latin America Pain-relieving Medications Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 48: Latin America Others Market Size (US\$ Mn) Analysis, 2012–2016

Figure 49: Latin America Others Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 50: Latin America Sickle cell anemia Market Size (US\$ Mn) Analysis, 2012–2016

Figure 51: Latin America Sickle cell anemia Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 52: Latin America Sickle Hemoglobin C Disease Market Size (US\$ Mn) Analysis, 2012–2016

Figure 53: Latin America Sickle Hemoglobin C Disease Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 54: Latin America Sickle Beta Thalassemia Market Size (US\$ Mn) Analysis, 2012–2016

Figure 55: Latin America Sickle Beta Thalassemia Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 56: Latin America Hospital Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 57: Latin America Hospital Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 58: Latin America Retail Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 59: Latin America Retail Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 60: Latin America Online Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 61: Latin America Online Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 62: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type

Figure 63: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type

Figure 64: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel

Figure 65: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country

Figure 66: Europe Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)

Figure 67: Europe Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)

Figure 68: Europe Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)

Figure 69: Europe Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)

Figure 70: Europe Sickle Cell Disease Treatment Market Value (US\$ Mn) & Forecast 2017 & 2025

Figure 71: Europe Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis, 2012–2016

Figure 72: Europe Sickle Cell Disease Treatment Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 73: Europe Hydroxyurea Market Size (US\$ Mn) Analysis, 2012–2016

Figure 74: Europe Hydroxyurea Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 75: Europe Antibiotics Market Size (US\$ Mn) Analysis, 2012–2016

Figure 76: Europe Antibiotics Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 77: Europe Pain-relieving Medications Market Size (US\$ Mn) Analysis, 2012–2016

Figure 78: Europe Pain-relieving Medications Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 79: Europe Others Market Size (US\$ Mn) Analysis, 2012–2016

Figure 80: Europe Others Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 81: Europe Sickle cell anemia Market Size (US\$ Mn) Analysis, 2012–2016

Figure 82: Europe Sickle cell anemia Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 83: Europe Sickle Hemoglobin C Disease Market Size (US\$ Mn) Analysis, 2012–2016

Figure 84: Europe Sickle Hemoglobin C Disease Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 85: Europe Sickle Beta Thalassemia Market Size (US\$ Mn) Analysis, 2012–2016

Figure 86: Europe Sickle Beta Thalassemia Market Size (US\$ Mn) & Y-o-Y Growth (%),

2017–2025

Figure 87: Europe Hospital Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 88: Europe Hospital Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 89: Europe Retail Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 90: Europe Retail Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 91: Europe Online Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 92: Europe Online Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 93: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type

Figure 94: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type

Figure 95: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel

Figure 96: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country

Figure 97: APAC Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)

Figure 98: APAC Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)

Figure 99: APAC Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)

Figure 100: APAC Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)

Figure 101: APAC Sickle Cell Disease Treatment Market Value (US\$ Mn) & Forecast 2017 & 2025

Figure 102: APAC Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis, 2012–2016

Figure 103: APAC Sickle Cell Disease Treatment Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 104: APAC Hydroxyurea Market Size (US\$ Mn) Analysis, 2012–2016

Figure 105: APAC Hydroxyurea Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 106: APAC Antibiotics Market Size (US\$ Mn) Analysis, 2012–2016

Figure 107: APAC Antibiotics Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 108: APAC Pain-relieving Medications Market Size (US\$ Mn) Analysis, 2012–2016

Figure 109: APAC Pain-relieving Medications Market Size (US\$ Mn) & Y-o-Y Growth

(%), 2017–2025

Figure 110: APAC Others Market Size (US\$ Mn) Analysis, 2012–2016

Figure 111: APAC Others Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 112: APAC Sickle cell anemia Market Size (US\$ Mn) Analysis, 2012–2016

Figure 113: APAC Sickle cell anemia Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 114: APAC Sickle Hemoglobin C Disease Market Size (US\$ Mn) Analysis, 2012–2016

Figure 115: APAC Sickle Hemoglobin C Disease Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 116: APAC Sickle Beta Thalassemia Market Size (US\$ Mn) Analysis, 2012–2016

Figure 117: APAC Sickle Beta Thalassemia Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 118: APAC Hospital Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 119: APAC Hospital Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 120: APAC Retail Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 121: APAC Retail Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 122: APAC Online Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 123: APAC Online Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 124: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type

Figure 125: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type

Figure 126: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel

Figure 127: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country

Figure 128: MEA Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)

Figure 129: MEA Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)

Figure 130: MEA Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)

Figure 131: MEA Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)

Figure 132: MEA Sickle Cell Disease Treatment Market Value (US\$ Mn) & Forecast

2017 & 2025

Figure 133: MEA Sickle Cell Disease Treatment Market Size (US\$ Mn) Analysis, 2012–2016

Figure 134: MEA Sickle Cell Disease Treatment Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 135: MEA Hydroxyurea Market Size (US\$ Mn) Analysis, 2012–2016

Figure 136: MEA Hydroxyurea Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 137: MEA Antibiotics Market Size (US\$ Mn) Analysis, 2012–2016

Figure 138: MEA Antibiotics Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 139: MEA Pain-relieving Medications Market Size (US\$ Mn) Analysis, 2012–2016

Figure 140: MEA Pain-relieving Medications Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 141: MEA Others Market Size (US\$ Mn) Analysis, 2012–2016

Figure 142: MEA Others Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 143: MEA Sickle cell anemia Market Size (US\$ Mn) Analysis, 2012–2016

Figure 144: MEA Sickle cell anemia Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 145: MEA Sickle Hemoglobin C Disease Market Size (US\$ Mn) Analysis, 2012–2016

Figure 146: MEA Sickle Hemoglobin C Disease Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 147: MEA Sickle Beta Thalassemia Market Size (US\$ Mn) Analysis, 2012–2016

Figure 148: MEA Sickle Beta Thalassemia Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 149: MEA Hospital Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 150: MEA Hospital Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 151: MEA Retail Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 152: MEA Retail Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 153: MEA Online Pharmacies Market Size (US\$ Mn) Analysis, 2012–2016

Figure 154: MEA Online Pharmacies Market Size (US\$ Mn) & Y-o-Y Growth (%), 2017–2025

Figure 155: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type

Figure 156: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type

Figure 157: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By

Distribution Channel

Figure 158: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country

Figure 159: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Region, 2017–2025

Figure 160: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Drug Type, 2017–2025

Figure 161: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Disease Type, 2017–2025

Figure 162: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Distribution Channel, 2017–2025

Figure 163: Global Sickle Cell Disease Treatment Market Value Analysis and Forecast, 2016–2025 (US\$ Mn)

Figure 164: Global Sickle Cell Disease Treatment Market Absolute \$ Opportunity (US\$ Mn), 2012–2016

Figure 165: Global Sickle Cell Disease Treatment Market Absolute \$ Opportunity (US\$ Mn), 2016–2025

I would like to order

Product name: Global Market Study on Sickle Cell Disease Treatment: Sickle Cell Anaemia Anticipated to be the Most Lucrative Disease Type Segment Through 2025

Product link: <https://marketpublishers.com/r/G36086A9180EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G36086A9180EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

